Next-generation therapies and technologies for immune-mediated inflammatory diseases. ([2017])

• Record Type: Book
• Further Information: Note: Paola Mina-Osorio, editor.
• Editors: Mina-Osorio, Paola
• Contents: Preface; Contents; List of Contributors; About the Editor; Part I: Diagnosis, Patient Stratification and Biomarkers; A Tale of Two Worlds; 1 Introduction; 2 The Many Faces of a Diagnosis; 3 Heterogeneity; 3.1 Prevalence of Heterogeneity; 3.2 Heterogeneity Due to Overlap; 3.2.1 Simultaneous; 3.2.2 Evolving Overlap; 3.2.3 Overlap with Non-rheumatic Autoimmune Illness; 3.2.4 Overlap That Does Not Meet Criteria; 3.3 Heterogeneity Due to Inapplicable Diagnosis and Treatment Guidelines; 4 Physician Inconsistency; 4.1 Inconsistent Diagnoses; 4.2 Inconsistent Treatment; 5 Effect of Time. 6 Variables Not Considered in Disease Activity, Severity, and Damage Scales7 The Problem with Mice as Proxies for Human Disease Measures; 8 What Is Precise Diagnosis?; 9 Proposals; 9.1 Stratify Patient Populations by Disease Process, Not by Diagnosis; 9.2 Seek Larger, Simpler Databases; References; Biomarkers in Clinical Trials for Rheumatoid Arthritis; 1 Introduction; 2 What Are Biomarkers?; 3 Biomarkers Currently Used in Rheumatoid Arthritis Clinical Trials; 3.1 Biomarkers as Inclusion Criteria for Clinical Trials; 4 Use of CRP or ESR in Clinical Trials for Rheumatoid Arthritis. 5 Diagnostic Biomarkers6 Rheumatoid Factor; 7 Anti-citrullinated Protein Antibodies; 8 14-3-3; 8.1 Disease Activity Biomarkers in RA; 9 Vectra® DA; 10 Validation of Rheumatoid Arthritis Biomarkers; 11 Technological Advancements in Testing for Biomarkers; 12 Main Challenges in Biomarker Discovery; 13 Emerging Trends in Biomarkers; 14 Potential Investment Required for Use in Clinical Trials; 15 Ethical and Legal Considerations; 16 Conclusion; References; The Role of Microparticles as Biomarkers in the Development of Therapy for Autoimmune Disease; 1 Introduction; 2 Generation of Microparticles. 3 The Assay of Microparticles4 The Functions of Microparticles; 5 MPs as a Source of DAMPs and Alarmins; 6 Microparticles as a Source of Immune Complexes; 7 Implications for New Therapies; 8 Conclusions; References; Part II: Genomic Medicine; The Future for Genomic Medicine in Inflammatory Diseases; 1 Expanding the Druggable Target Universe; 2 A Brief History of Genomic Modalities; 2.1 Antisense; 2.2 RNA Interference; 2.3 MicroRNA; 2.4 Gene Therapy; 2.5 Genome Editing; 3 State of the Art in Genomic Medicine; 4 Barriers to Successful Gene Therapy: Cystic Fibrosis as a Case Study. 5 The Rise and Fall and Rise of Genomic Medicine in the Pharma and Biotech Sectors6 Genomic Medicine and Inflammatory Diseases; 7 Converting the Promise of Genomic Medicine into Reality for Inflammatory Diseases; 7.1 Delivery; 7.2 Target; 7.3 Development Path; 7.4 Target Regulation; 7.5 Control of Expression; 7.6 Superior Efficacy Versus Standard of Care; 7.7 Costs; 8 Summary; References; Part III: Bispecific Antibodies; Bispecific Antibodies; 1 Introduction; 2 Rationale for Bispecific Biologics in Rheumatoid Arthritis; 2.1 Mode of Action of Biologics in RA and Combination Therapies.
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2017
• Extent: 1 online resource
• Subjects: 616/.0473; Medicine; Inflammation -- Immunological aspects; Immune System Diseases -- therapy; MEDICAL -- Pathology; Inflammation -- Immunological aspects; Biomedicine; Immunology; Pharmaceutical Sciences/Technology; Gene Therapy; Pharmacy; Medical -- Pharmacy; Medical -- Genetics; Pharmaceutical technology; Medical genetics; Pharmacy / dispensing; Immunology; Pharmaceutical technology; Gene therapy; Pharmacy; Medical -- Immunology; Immunology; Electronic books
• Languages: English
• ISBNs: 9783319422527; 3319422529
• Related ISBNs: 9783319422510; 3319422510
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (SpringerLink, viewed February 3, 2017).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.